Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-β

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 401-408

  Bielenberg, Diane R ^a   Bucana, Corazon D ^a   Sanchez, Ricardo ^a   Mulliken, John B ^b   Folkman, Judah ^b   Fidler, Isaiah J ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Cutaneous hemangiomas; Epidermal hyperplasia; Interferon beta

Indexed keywords

ANGIOGENIC FACTOR; BETA INTERFERON;

ARTICLE; BIOSYNTHESIS; CAPILLARY HEMANGIOMA; CELL DIVISION; DISEASE COURSE; DOWN REGULATION; EPIDERMIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYPERPLASIA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR;

ANGIOGENESIS INDUCING AGENTS; CELL DIVISION; DISEASE PROGRESSION; DOWN-REGULATION; EPIDERMIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOMA, CAPILLARY; HUMANS; HYPERPLASIA; INFANT, NEWBORN; INTERFERON-BETA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

EID: 0033089048     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Folkman J: Towards a new understanding of vascular proliferative disease in children. Pediatrics 74: 850-856, 1984.
2. Mulliken JB and Young AE: Vascular birthmarks: hemangiomas and malformations. WB Saunders, Philadelphia, pp41-76, 1988.
3. Folkman J, Mulliken JB and Ezekowitz RAB: Antiangiogenic therapy of hemangiomas with interferon-alpha. In: Clinical applications of the interferons. Stuart-Harris R, Penny R (eds.) Chapman and Hall, London pp255-265, 1997.
4. White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF and Yu A: Treatment of childhood angiomatous diseases with recombinant interferon alpha-2A. J Pediatr 118: 59-66, 1991.
5. Ezekowitz RAB, Mulliken JB and Folkman J: Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Eng J Med 333: 575-576, 1995.
6. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med 1: 27-31, 1985.
7. Auerbach W and Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther 63: 265-311, 1994.
8. Cockerill GW, Gamble JR and Vadas MA: Angiogenesis: models and modulators. Int Rev Cytol 159: 113-160, 1995.
9. Klagsbrun M and D'Amore PA: Regulators of angiogenesis. Ann Rev Physiol 53: 217-239, 1991.
10. Fidler IJ and Ellis LM: The implications of angiogenesis to the biology and therapy of cancer metastasis (mini-review). Cell 79: 185-188, 1994.
11. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R and Klagsbrun M: Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 29: 275-287, 1985.
12. Montesano R, Vassalli JD, Baird A, Guillemin R and Orci L: Basic fibroblast growth factor induces angiogenesis in vivo. Proc Natl Acad Sci USA 83: 7297-7301, 1986.
13. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
14. Ferrara N, Houck KA, Jakeman LB, Winer J and Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991.
15. Takahashi K, Mulliken JB, Kozakewich HPW, Rogers RA, Folkman J and Ezekowitz RAB: Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93: 2357-2364, 1994.
16. Chang J, Most D, Bresnick S, Reinisch J, Longaker MT and Turk AE: Gene expression of basic fibroblast growth factor and vascular endothelial growth factor is upregulated in proliferating hemangiomas: a possible mechanism of angiogenesis. Surg Forum, 83rd Ann Clin Cong 48: 686-688, 1997.
17. Isaacs A and Lindenmann J: Virus interference. I. The interferon. Proc R Soc Ser B 147: 258-267, 1957.
18. Yaar M, Karassik RL, Schnipper LE and Gilchrest BA: Effects of alpha and beta interferons on cultured human keratinocytes. J Invest Dermatol 85: 70-74. 1985.
19. Thomas H and Balkwill FR: Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 52: 307-330, 1991.
20. Tamm I, Lin SL, Pfeiffer LM and Sehgal PB: Interferons α and β as cellular regulatory molecules. In: Interferon 9. Gresser I (ed.). Academic Press, London, pp14-73, 1987.
21. Resnitzky D, Yarden A, Zipori D and Kimchi A: Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation. Cell 46: 31-40, 1986.
22. Gresser I, Carnaud C, Maury C, Sala A, Eid P, Woodrow D, Maunoury MT and Belardelli F: Host immunity and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α/β treatment in mice. J Exp Med 173: 1193-1203, 1991.
23. Gresser I: Antitumor effects of interferons. Acta Oncol 28: 347-353, 1989.
24. Gutterman JU: Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci USA 91: 1198-1205, 1994.
25. Sinkovics JG: Interferons: antiangiogenesis agents (a reasonable theory). Cancer J Infect Diseases 3: 128B-132B, 1992.
26. Heyns A, Eldor A, Vlodavsky I, Kaiser N, Fridman R and Panet A: The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Exp Cell Res 161: 297-306, 1985.
27. Friesel R, Komoriya A and Maciag T: Inhibition of endothelial cell proliferation by γ-interferon. J Cell Biol 104: 689-696, 1987.
28. Ruszczak Z, Detmar M, Imcke E and Orfanos C: Effects of rIFN-α, -β, and -γ on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 95: 693-699, 1990.
29. Hicks C and Penny R: Response of microvascular endothelial cells to biological response modifiers. Immunol Cell Biol 67: 271-277, 1989.
30. Brouty-Boye D and Zetter BR: Inhibition of cell motility by interferon. Science 208: 516-518, 1980.
31. Fukuzawa K and Horikoshi T: Inhibitory effect of human fibroblast interferon (HuIFN-β) on the growth and invasive potential of cultured human melanoma cells in vitro. Br J Dermatol 126: 324-330, 1992.
32. Stout AJ, Gresser I and Thompson WD: Inhibition of wound healing in mice by local interferon α/β injection. Int J Exp Pathol 74: 79-85, 1993.
33. Dvorak HF and Gresser I: Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 81: 497-502, 1989.
34. Sidky YA and Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47: 5155-5161, 1987.
35. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR and Fidler IJ: Organ-site dependent expression of bFGF in human renal cell carcinoma cells. Am J Pathol 145: 365-374, 1994.
36. Oliveira IC, Sciavolino PJ, Lee TH and Vilcek J: Downregulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 89: 9049-9053, 1992.
37. Van Damme J and Opdenakker G: Interaction of interferons with skin reactive cytokines: from interleukin-1 to interleukin-8. J Invest Dermatol 95: 905-935, 1990.
38. Singh RK, Gutman M, Llansa N and Fidler IJ: Interferon-beta prevents the upregulation of interleukin-8 expression in human melanoma cells. J Interferon Cytokine Res 16: 577-584, 1996.
39. Singh RK, Bucana CD, Llansa N, Sanchez R and Fidler IJ: Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int J Oncol 8: 649-656, 1996.
40. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N and Fidler IJ: Interferons α and β downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92:4562-4566, 1995.
41. Fabra A, Nakajima M, Bucana CD and Fidler IJ: Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 52: 101-110, 1992.
42. Gohji K, Fidler IJ, Tsan R, Radinsky R, von Eschenbach AC, Tsuruo T and Nakajima M: Human recombinant interferons β and γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int J Cancer 58: 380-384, 1994.
43. Kato N, Nawa A, Tamakoshi K, Kikkawa F, Suganuma N, Okamoto T, Goto S, Tomoda Y, Hamaguchi M and Nakajima M: Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-beta. Am J Obstet Gynecol 172: 601-606, 1995.
44. Singh RK, Llansa N, Bucana CD, Sanchez R, Koura A and Fidler IJ: Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth Differ 7: 397-404, 1996.
45. Takahashi JA, Mori H, Fukumoto M, Igarashi K, Jaye M, Oda Y, Kikuchi H and Hatnaka M: Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 87: 5710-5714, 1990.
46. Takami K, Iwane M, Kiyota Y, Miyamoto M, Tsukuda R and Shiosaka S: Increase of basic fibroblast growth factor immunoreactivity and its mRNA level in rat brain following transient forebrain ischemia. Exp Brain Res 90: 1-10, 1992.
47. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR and Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541-546, 1997.
48. Takahashi Y, Bucana CD, Cleary KR and Ellis LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 79: 34-38, 1998.
49. Shi S, Key ME and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
50. Kitadai Y, Ellis LM, Tucker SL, Greene GF, Bucana CD, Cleary KR, Takahashi Y, Tahara E and Fidler IJ: Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 149: 1541-1551, 1996.
51. Greene G, Kitadai Y, Pettaway CA, von Eschenbach AC and Fidler IJ: Correlation of metastasis-related gene expression with metastatic potential in prostate carcinoma cells implanted in nude mice using an in situ mRNA hybridization technique. Am J Pathol 150: 1571-1582, 1997.
52. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD and Fidler IJ: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90: 447-454, 1998.
53. Pearson WR and Lipman DL: Improved tools for biological sequence comparison. Proc Natl Acad Sci USA 85: 2444-2448, 1988.
54. Bucana CD, Radinsky R, Dong Z, Sanchez R, Brigati DJ and Fidler IJ: A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr-1 in mouse colon carcinoma cells. J Histochem Cytochem 41:499-506, 1993.
55. Radinsky R, Bucana CD, Ellis LM, Sanchez R, Cleary KR, Brigati DJ and Fidler IJ: A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res 53: 937-943, 1993.
56. Caruthers MH, Beaucage SL, Efcavitch JW, Fisher EF, Goldman RA, DeHaseth PL, Mandecki W, Matteucci MD, Rosenthal MS and Stabinsky Y: Chemical synthesis and biological studies on mutated gene-control regions. Cold Spring Harbor Symp Quant Biol 47:411-418, 1982.
57. Boon LM, Enjolras O and Mulliken JB: Congenital hemangioma: evidence of accelerated involution. Pediatrics 128: 331-335, 1996.
58. Koura AN, Liu W, Kitadai Y, Singh RK, Radinsky R and Ellis LM: Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 56: 3891-3894, 1996.
59. Wineland M, Ahearn P, Bielenberg D, Bucana CD and Fidler IJ: Melanoma-induced epidermal hyperplasia increases angiogenesis of the lesion. Proc Amer Assoc Cancer Res 39: 375-376, 1998.
60. Sen G and Ransohoff RM: Interferon-induced antiviral actions and their regulation. Adv Virus Res 42: 57-102, 1993.
61. Uze G, Lutgalla G and Morgensen LE: Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res 15: 3-26, 1995.
62. Abramovich C, Shulman LM, Ratovitski E, Harroch S, Tovey M, Eid P and Revel M: Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-α and IFN-β. EMBO J 13: 5871-5877, 1994.
63. Ezekowitz A, Mulliken J and Folkman J: Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 79: 67-68, 1991.
64. Ricketts RR, Hatley RM, Corden BJ, Sabio H and Howell CG: Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 6: 605-614, 1994.
65. Ohlms LA, McGill TJI, Jones DT and Healy GB: Interferon-alpha-2A therapy for airway hemangiomas. Ann Otol Rhinol Laryngol 103: 1-8, 1994.
66. Deb G, Donfrancesco A, DeSio L and Standoli L: Treatment of hemangiomas of infants and babies with interferon-alpha-2a: preliminary results. J Pediatr Haematol Oncol 3: 109-113, 1996.
67. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, Folkman J, Ezekowitz RA and Castle VP: Successful treatment of infantile hemangiomas with interferon-α-2b. J Pediatr Haematol Oncol 19: 237-244, 1997.
68. Soumekh B, Adams GL and Shapiro RS: Treatment of head and neck hemangiomas with recombinant interferon-alpha-2b. Ann Otol Rhinol Laryngol 105: 201-206, 1996.
69. Orchard PJ, Smith CM, Woods WG, Day DL, Dehner LP and Shapiro R: Treatment of heamangio-endotheliomas with alpha interferon. Lancet ii: 565-567, 1989.
70. White CW, Sondheimer HM, Crouch EC, Wilson H and Fan LL: Treatment of pulmonary hemangiomatosis with recombinant interferon-alpha-2a. N Engl J Med 320: 1197-1200, 1989.
71. Kirn DH and Kramer A: Long-term freedom from disease progression with interferon alpha therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 88: 764-765, 1996.
72. Sakar M, Mulliken JB, Kozakewich HPW, Robertson RL and Burrows PE: Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common hemangioma. Plast Reconstr Surg 100: 1377-1386, 1997.
73. Roudier-Pujol C, Enjolras O, Lacronique J, Guillemette J, Herbreteau D, Leibowitch M and Escande JP: Multifocal epithelioid hemangioendothelioma with partical remission after interferon alpha-2a treatment. Ann Dermatol Venereol 121: 898-904, 1997.
74. Evans LM, Itri LM, Campion M, Wyler-Plaut R, Krown SE, Groopman JE, Goldsweig H, Volberding PA, West SB, Mitsuyasu RT and Dziewanowska ZE: Interferon-α2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother 10: 39-51, 1991.
75. Real FX, Oettgen HF and Krown SE: Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte α interferon. J Clin Oncol 4: 544-551, 1986.
76. Rios A, Mansell PW, Newell GR, Reuben JM, Hersh EM and Gutterman JU: Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol 3: 506-512, 1985.
77. Mitsuyasu RT: Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol 79: 69-73, 1991.
78. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res 50: 6130-6138, 1990.
79. Fidler IJ: Modulation of the organ microenvironment for the treatment of cancer metastasis (commentary). J Natl Cancer Inst 87: 1588-1592, 1995.